MEI Pharma, Inc. (MEIP) Forms $3.13 Double Bottom; Profile of 3 Analysts Covering AAC Holdings, Inc. (AAC)

AAC Holdings, Inc. (NYSE:AAC) Logo

Among 4 analysts covering AAC Holdings Inc (NYSE:AAC), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AAC Holdings Inc had 15 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was upgraded by Mizuho on Wednesday, May 25 to “Buy”. The stock has “Mkt Perform” rating by Raymond James on Thursday, November 3. The firm has “Buy” rating by William Blair given on Monday, September 21. The rating was maintained by Cantor Fitzgerald with “Buy” on Sunday, May 13. The stock of AAC Holdings, Inc. (NYSE:AAC) earned “Outperform” rating by William Blair on Friday, August 21. The firm has “Underperform” rating by Mizuho given on Wednesday, November 9. Raymond James upgraded AAC Holdings, Inc. (NYSE:AAC) on Friday, November 3 to “Buy” rating. Mizuho initiated AAC Holdings, Inc. (NYSE:AAC) on Monday, August 3 with “Neutral” rating. The firm has “Neutral” rating by Mizuho given on Tuesday, May 30. The stock has “Strong Buy” rating by Raymond James on Monday, August 15. See AAC Holdings, Inc. (NYSE:AAC) latest ratings:

13/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $14.0000 Maintain

MEI Pharma, Inc. (MEIP) formed double bottom with $3.00 target or 4.00% below today’s $3.13 share price. MEI Pharma, Inc. (MEIP) has $116.82 million valuation. The stock decreased 0.95% or $0.03 during the last trading session, reaching $3.13. About 476,616 shares traded or 74.36% up from the average. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 32.91% since May 27, 2017 and is uptrending. It has outperformed by 21.36% the S&P500.

Among 4 analysts covering MEI Pharma (NASDAQ:MEIP), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. MEI Pharma had 8 analyst reports since September 4, 2015 according to SRatingsIntel. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) rating on Wednesday, May 31. Oppenheimer has “Buy” rating and $6.5000 target. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) rating on Wednesday, June 14. Oppenheimer has “Buy” rating and $6.5000 target. Oppenheimer maintained it with “Buy” rating and $6.5000 target in Wednesday, August 2 report. As per Monday, June 26, the company rating was maintained by Oppenheimer. On Friday, September 4 the stock rating was maintained by Wedbush with “Hold”. The firm has “Hold” rating given on Wednesday, September 6 by Stifel Nicolaus.

Analysts await MEI Pharma, Inc. (NASDAQ:MEIP) to report earnings on September, 4. They expect $-0.28 EPS, down 133.33% or $0.16 from last year’s $-0.12 per share. After $-0.16 actual EPS reported by MEI Pharma, Inc. for the previous quarter, Wall Street now forecasts 75.00% negative EPS growth.

Another recent and important AAC Holdings, Inc. (NYSE:AAC) news was published by which published an article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within MSA Safety Incorporated, Curis, American States …” on May 21, 2018.

AAC Holdings, Inc. provides inpatient substance abuse treatment services for individuals with drug and alcohol addiction in the United States. The company has market cap of $280.49 million. The Company’s therapy services include motivational interviewing, cognitive behavioral therapy, rational emotive behavior therapy, dialectical behavioral therapy, solution-focused therapy, eye movement desensitization and reprocessing, and systematic family intervention services. It currently has negative earnings. As of December 31, 2016, the firm operated 12 residential substance abuse treatment facilities, 18 standalone outpatient centers, and 202 sober living beds.

MEI Pharma, Inc. (NASDAQ:MEIP) Institutional Positions Chart